Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04241328

Medtronic SYMBIOSIS Post-Market Registry for Patients Undergoing Cardiac Surgery

The purpose of this observational, multi-center prospective, post-market registry is to confirm real-world device safety and performance, to ensure the continued acceptability of identified risks, and detect emerging risks.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

AKH Wien, Vienna, Austria

Loading trial locations.

About this study

The objective is to collect product safety and performance data for Medtronic CE (Conformitè Europëenne )-Marked Cardiac Surgery, including perfusion (CS) products.

The main goals of this data collection are as follows:

  • Identification of any (new) device-related complications including events which were not anticipated or documented in the Instructions For Use (IFU), or Risk Management Plan, or Clinical Evidence Evaluation report, or Design Failure Modes and Effect Analysis
  • Evaluation of device success defined as the absence of any probable or causal device-related adverse events or device deficiencies
  • Evaluation of general device performance when applicable

Subjects are enrolled and, if applicable, followed according to routine care practices at their treating hospital.

Inclusion criteria

  • Subject or legally authorized representative provides written data release and/or informed consent per institution and/or geographical requirements prior to discharge from participating Registry hospital.
  • Subject will undergo or underwent a procedure in which an eligible Medtronic CS product is/was used.

Exclusion criteria

  • Currently participating in an interventional drug or device study which may induce confounding factor(s) to the results from this Registry

Data collection includes, for example:

  • Demographics
  • Product performance information
  • Safety Events

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject or legally authorized representative provides written data release and/or informed consent per institution and/or geographical requirements prior to discharge from participating registry hospital.
  • Subject will undergo or underwent a procedure in which an eligible Medtronic CS product is/was used.

Exclusion criteria

  • Currently participating in an interventional drug or device study which may induce confounding factor(s) to the results from this Registry

Treatment and study plan

Primary outcomes

  1. Device Safety

    Time frame: Procedural

    Procedure- , device-related events and device deficiencies

  2. Device performance

    Time frame: Procedural

    Device Success

Study contacts

Contact information is provided by the study sponsor or research team.

Lisa Lindelauf, BSc

CONTACT

[email protected]

+31611605434

Sponsors and collaborators

Lead sponsor

Medtronic Cardiac Surgery

Industry

Registry information

Official study title

SYMBIOSIS Post-Market Registry

Acronym: SYMBIOSIS

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Jan 27, 2020
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.